CGEM
Cullinan Therapeutics, Inc.
$7.44
0.25
(3.48%)
| Exchange: | |
| Market Cap: | 439.523M |
| Shares Outstanding: | 11.45M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Pharmaceuticals | |||||
| CEO: | Nadim Ahmed | |||||
| Full Time Employees: | 111 | |||||
| Address: |
|
|||||
| Website: | https://cullinantherapeutics.com |
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Click to read more…
Revenue Segmentation
EPS
Earnings Call
Income Statement
(* All numbers are in thousands)
Balance Sheet
(* All numbers are in thousands)
Cash Flow Statement
(* All numbers are in thousands)
Analyst Estimates
(* All numbers are in thousands)
